Piper Sandler raises target for Moderna stock to USD 230.00

Published on 10/27/2026 at 17:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 145.00 million in second quarter. Moderna stock costs EUR 176.05 on October 27, 2026, up 1.11 percent versus Xetra close.

Piper Sandler lifts target

Piper Sandler raised its Moderna target from USD 167.00 to USD 230.00 on October 26, 2026.
Second-quarter revenue reached USD 145.00 million, up 2.00 percent year over year.
Moderna stock costs EUR 176.05 at Lang & Schwarz on October 27, 2026 at 5:07 p.m. CEST, 1.11 percent above the Xetra close of EUR 174.12.
Moderna is scheduled to report third-quarter 2026 results on November 6, 2026.

Moderna Inc., US60770K1079, Illustration mit AI erstellt.

Moderna Inc. (ISIN US60770K1079) became the subject of a higher valuation target after Piper Sandler raised its price target from USD 167.00 to USD 230.00 on October 26, 2026, according to MarketScreener. Moderna stock was trading at EUR 176.05 at Lang & Schwarz on October 27, 2026 at 5:07 p.m. CEST, up 1.11 percent versus the Xetra close of EUR 174.12 on October 26, 2026.

Second-quarter revenue improved

Moderna generated USD 145.00 million in revenue in the second quarter of 2026, up 2.00 percent from USD 142.00 million in the second quarter of 2025. The company reported a net loss of USD 782.00 million, improving by USD 43.00 million, or 5.00 percent, from the prior-year quarter, according to the Yahoo Finance transcript.

What does the target imply?

Piper Sandler's USD 230.00 target stands 17.03 percent above Moderna's USD 196.53 Nasdaq price at the time of the October 27, 2026 finance quote. The target therefore points to a different valuation frame from the current consensus: MarketScreener listed a USD 138.37 average target from 23 analysts on October 26, 2026.

Results date and valuation

MarketScreener's calendar lists November 6, 2026 as Moderna's third-quarter 2026 earnings release date. The company also said in its second-quarter call that it would hold an Analyst Day on November 12, 2026, according to Yahoo Finance.

On the Nasdaq, Moderna was last quoted at USD 196.53 on October 27, 2026 at 12:13 p.m. EDT. Its USD 78.6 billion market capitalization and negative trailing P/E of 24.58 place the stock in a valuation discussion shaped by future pipeline revenue rather than current earnings.

Comparison with peers

Moderna: 1.11 percent above the Xetra close, P/E minus 24.58, market capitalization USD 78.6 billion.

BioNTech (Nasdaq, USD): down 0.24 percent, P/E minus 11.53, market capitalization USD 21.8 billion.

Gilead Sciences (Nasdaq, USD): down 0.78 percent, P/E minus 58.93, market capitalization USD 195.2 billion.

Stock position after the target change

Moderna's USD 22.28 to USD 254.48 52-week range leaves the Nasdaq price 22.77 percent below the high and 782.30 percent above the low as of October 27, 2026. For investors, the November reporting date is the next concrete test of whether the company's revenue trajectory can support the raised target.

The further course of trading is shown by the continuously updated real-time quote of Moderna stock.